Director Holcomb of MiNK Therapeutics (NASDAQ: INKT) receives 4,174 stock options grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
MiNK Therapeutics director John Bradley Holcomb received a grant of stock options covering 4,174 shares of common stock. The options have an exercise price of $14.92 per share and were awarded under the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan. They vest in three equal annual installments on September 23, 2026, 2027 and 2028, as long as Dr. Holcomb continues his service relationship with the company. Following this grant, he holds 4,174 options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Holcomb John Bradley
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 4,174 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 4,174 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 4,174 options
Exercise price: $14.92 per share
Underlying shares: 4,174 shares
+2 more
5 metrics
Options granted
4,174 options
Stock Option (Right to Buy) grant to director
Exercise price
$14.92 per share
Conversion or exercise price of stock options
Underlying shares
4,174 shares
Common Stock underlying the options
Post-transaction options held
4,174 options
Total options following transaction
Option expiration
September 23, 2035
Expiration date of the stock options
Key Terms
Stock Option (Right to Buy), exercise price, Equity Incentive Plan, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "14.9200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Equity Incentive Plan financial
"MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
vesting financial
"will vest in three equal annual installments on each of September 23, 2026, 2027 and 2028"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2035-09-23T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did MiNK Therapeutics (INKT) director John Bradley Holcomb report in this Form 4?
Dr. John Bradley Holcomb reported receiving a grant of stock options for 4,174 shares of MiNK Therapeutics common stock. These options are a compensation award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price.
What are the key terms of John Bradley Holcomb’s MiNK Therapeutics stock option grant?
The grant covers 4,174 options with an exercise price of $14.92 per share. The options were awarded under MiNK Therapeutics’ 2021 Amended and Restated Equity Incentive Plan as a director compensation award, with vesting tied to continued service with the company.
How do John Bradley Holcomb’s MiNK Therapeutics options vest over time?
The options vest in three equal annual installments on September 23, 2026, September 23, 2027, and September 23, 2028. Vesting depends on Dr. Holcomb maintaining a service relationship with MiNK Therapeutics through each specified vesting date.
How many MiNK Therapeutics options does John Bradley Holcomb hold after this transaction?
After this grant, Dr. Holcomb holds 4,174 stock options directly. Each option represents the right to purchase one share of MiNK Therapeutics common stock at the fixed exercise price once the options have vested and are exercisable.